HUTCHMED’s Sovleplenib Gains FDA Orphan Drug Designation
The US FDA granted orphan drug designation to HUTCHMED’s sovleplenib for autoimmune hemolytic anemia.
The US FDA granted orphan drug designation to HUTCHMED’s sovleplenib for autoimmune hemolytic anemia.